Abstract

Survivors of childhood central nervous system (CNS) tumors experience early-onset aging-related phenotypes. DNA methylation (DNAm) age is an emerging epigenetic biomarker of physiologic age and may be predictive of chronic health conditions in long-term survivors. This report describes the course of epigenetic age acceleration using post-diagnosis blood samples (median: 3.9 years post-diagnosis; range: 0.04-15.96) from 83 survivors of pediatric CNS tumors. Epigenetic age acceleration was detected in 72% of patients, with an average difference between chronologic and DNAm age of 2.58 years (95% CI: 1.75-3.41, p < 0.001). Time from diagnosis to sample collection correlated with the magnitude of epigenetic age acceleration.

 抽象的

儿童中枢神经系统（CNS）肿瘤的幸存者会经历早发的衰老相关表型。 DNA 甲基化 (DNAm) 年龄是一种新兴的生理年龄表观遗传生物标志物，可以预测长期幸存者的慢性健康状况。本报告使用 83 名小儿中枢神经系统肿瘤幸存者的诊断后血液样本（中位：诊断后 3.9 年；范围：0.04-15.96）描述了表观遗传年龄加速的过程。 72% 的患者检测到表观遗传年龄加速，实际年龄和 DNAm 年龄之间的平均差异为 2.58 岁（95% CI：1.75-3.41， p < 0.001）。从诊断到样本采集的时间与表观遗传年龄加速的程度相关。